The California-based biotech continued its rocket-like ascent in 2015–just two years ago it ranked No. 250 on the 500–due to booming sales of its breakthrough Hepatitis C medications. Those drugs–Sovaldi and Harvoni–which cost a fortune, but also cure a chronic, devastating disease, sparked a national debate on drug pricing. They also drove Gilead’s bottom and top lines in 2015–revenues and profits jumped 31% and 50%, respectively. John Milligan, Gilead’s new CEO faces rockier road in 2016: the competition is stiffer and IP challenges and pricing pressures loom.
News about Gilead Sciences
From a possible vaccine to potential functional cures.
Tesaro shares skyrocketed on data about its ovarian cancer drug.
It's Gilead's Epclusa, and it's less pricey than expected.
Gilead Sciences, Walmart, and Wells Fargo are the most charitable companies in the Fortune 500.